At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 256 enrolled
Drug / intervention
MT-5199 +1 moredrug
Likely dose
MT-5199 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)
In Brief
A Phase 3 clinical trial evaluating MT-5199 and Placebo for Tardive Dyskinesia. Completed, enrolled 256 participants across 82 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTardive Dyskinesia
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartJun 2017
Primary CompletionSep 2020
TodayJul 2026
First PostedJun 5, 2017
Enrollment StartJun 21, 2017
Primary CompletionSep 29, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.1 years ago
Interventions
MT-5199drug
MT-5199 40 mg capsules
Placebodrug
MT-5199 placebo capsules